Managed Entry Agreements and High Cost Medicines (European Perspective)

Risultato della ricerca: Capitolo in libro/report/atti di convegnoContributo in volume (Capitolo o Saggio)peer review

Abstract

This chapter provides an overview on Managed Entry Agreements (MEA). Managed Entry Agreements are contracts between the industry and payers under which a drug gets access to the market. The first two sessions illustrate the rationale and taxonomy of MEA, that could be designed as financial-based or outcome-based agreement. The third one describes how these agreements have been implemented in Europe. The fourth section illustrates the results of the few studies that have investigated the impact of MEA and some thoughts on future perspectives for these contracts.

Lingua originaleInglese
Titolo della pubblicazione ospiteEquitable Access to High-Cost Pharmaceuticals
EditoreElsevier
Pagine35-49
Numero di pagine15
ISBN (elettronico)9780128119457
ISBN (stampa)9780128119624
DOI
Stato di pubblicazionePubblicato - 1 gen 2018

Fingerprint

Entra nei temi di ricerca di 'Managed Entry Agreements and High Cost Medicines (European Perspective)'. Insieme formano una fingerprint unica.

Cita questo